Page 3 - Natco Pharma

Natco Pharma receives warning letter from USFDA for Telangana plant

Natco Pharma on Tuesday said it has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility. The inspection was conducted by USFDA from October 9 to October 18, 2023. "We wish to inform you that the company has received a warning letter dated April 8, 2024 from the USFDA," the drug firm said in a regulatory filing. The company does not believe that the warning letter will have an impact on supplies or the existing revenues from this facility, it added. "It may cause delay/withholding of pending product approvals from this site," Natco Pharma said. The drug firm will respond to the letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance, it said. A warning letter is issued when the US

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Natco Pharma Q2 results: Net profit surges over 6-fold to Rs 369 cr

Natco Pharma on Tuesday reported an over six-fold jump in its consolidated net profit to Rs 369 crore in the second quarter ended September 30, 2023. The Hyderabad-based drug firm had reported a net profit of Rs 57 crore in the July-September period of last fiscal. Consolidated total revenue rose to Rs 1,061 crore for the period under review, as compared with Rs 453 crore in the year-ago period, Natco Pharma said in a regulatory filing. The company reported strong performance during the quarter due to growth in formulation exports and increased sales in the domestic agrochemical business, it added.

Natco Pharma, Celgene Corp, others sued in US for generic cancer drug

Natco Pharma on Friday said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US. The Hyderabad-based drug firm along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others have been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide. The company believes this matter is without merit, Natco Pharma said in a statement. Breckenridge is the abbreviated new drug application (ANDA) holder and distribution partner for the generic product in the US, it added. Natco Pharma shares were trading 3.13 per cent down at Rs 885.00 apiece on the BSE.

Natco Pharma's net profit rises 31.2% to Rs 420.3 cr in June quarter

Natco Pharma Ltd on Wednesday reported a 31.2 per cent rise in consolidated net profit at Rs 420.3 crore in the first quarter ended June 30, 2023. The company had posted a consolidated net profit of Rs 320.4 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 1,140.5 crore as against Rs 884.6 crore in the year-ago period, it added. Total expenses were higher at Rs 660.2 crore as compared to Rs 533.1 crore a year ago. The major drivers of business during the June quarter were formulation exports, strong growth in domestic business of both pharma and agro, and steady sales from subsidiaries, the company said. Exports of formulations clocked Rs 884.2 crore in the April-June quarter from Rs 736.9 crore a year ago, while domestic formulations registered Rs 132.4 crore, up from Rs 88.5 crore last year, it added. The active pharmaceutical ingredients segment posted Rs 75.1 crore,

Stocks to watch: Tata Steel, NMDC, PNC Infra, Natco Pharma, MTAR Tech

Stocks to watch on June 19, 2023: From Tata Steel to NMDC, here are the top stocks to watch in Monday's trading session

Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

Natco Pharma jumps 4% on filing generic version of oncology drug in US

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Broad-based rally lifts Sensex 578pts, Nifty above 17,800; pharma stks lead

CLOSING BELL: Besides, the Nifty Auto and Private Bank indices advanced 1.7 per cent each

Stocks to Watch: IRCTC, McLeod Russel, Sugar, Adani Ports, Gail, Dish TV

Stocks to Watch Today: Oil related shares are likely to be in focus on Tuesday as the oil ministry sought a review of the windfall profit tax on domestically produced crude oil.

Stocks to Watch: GAIL, Sona BLW, ONGC, Natco Pharma, RIL, Airtel, Vodafone

Stocks to Watch: Blackstone Inc. is seeking to raise as much as Rs 3,180 crore ($400 million) through the sale of shares in Indian automotive component maker Sona Comstar

Sensex leaps 1,163 pts from the day's low, ends 581 pts up; Nifty tops 16K

CLOSING BELL: The winners included Indian Oil Corporation, Sun Pharma, Tata Consumer Products, TCS, Cipla, Shree Cement, NTPC, Tech M, Dr Reddy's Labs, Wipro, Ultratech Cement, and Infosys

Here's why HDFC Securities recommends buying VRL Logistics, Natco Pharma

Logistics stocks have been showing strength on the medium term charts, according to Vinay Rajani of HDFC Securities.

Natco board approves proposal to acquire US-based pharma company

The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said

Natco Pharma launches novel drug for colorectal, gastric cancer

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle, Natco Pharma said in a regulatory filing. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer. In India, around 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need, the drug maker said. The company said it has launched the medication at an affordable price.

Dr Reddy's, Natco Pharma launch generic cancer drug in Canada

Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.

Natco Pharma slips 6% as Delhi HC allows injunction application by FMC Corp

The Hon'ble High Court of Delhi today orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR

Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug

The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US

Natco gets approval for emergency use of Baricitinib for Covid-19 treatment

Natco Pharma has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India